Relmada Therapeutics recently disclosed that its phase 3 second-line study targeting BCG non-responsive patient groups is expected to yield preliminary 3-month efficacy data by the end of 2026.
Show original
This study is a key milestone in the advancement of the company's core pipeline, and its results are closely watched by the industry.
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
PoolX: Earn new token airdrops
Lock your assets and earn 10%+ APR
Lock now!
You may also like
Crypto trading platform and wallet service provider Blockchain.com will enter the Ghana market.
ForesightNews•2026/03/10 00:52
Tagged as BitMine Wallet, 3 hours ago transferred 5300 ETH to an exchange
BlockBeats•2026/03/10 00:35
Trending news
MoreCrypto prices
More
Bitcoin
BTC
$69,131.45
+4.24%
Ethereum
ETH
$2,015.11
+3.43%
Tether USDt
USDT
$1
+0.04%
BNB
BNB
$639.22
+3.78%
XRP
XRP
$1.37
+1.45%
USDC
USDC
$1
+0.03%
Solana
SOL
$85.71
+3.82%
TRON
TRX
$0.2857
-1.30%
Dogecoin
DOGE
$0.09117
+1.41%
Cardano
ADA
$0.2579
+2.53%
How to buy BTC
Bitget lists BTC – Buy or sell BTC quickly on Bitget!
Trade now
Become a trader now?A welcome pack worth 6200 USDT for new users!
Sign up now